Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021
Journal of Hematology & Oncology,
Год журнала:
2025,
Номер
18(1)
Опубликована: Янв. 10, 2025
Female-specific
cancers,
particularly
breast,
cervical,
ovarian,
and
uterine
account
for
nearly
40%
of
all
cancers
in
women.
This
study
aimed
to
analyze
the
global
epidemiological
trends
these
from
1990
2021,
offering
insights
into
their
evolving
patterns
providing
valuable
information
health
policymakers
allocate
healthcare
resources
more
effectively.
Data
Global
Burden
Disease
Study
2021
(GBD
2021)
were
used
comprehensively
assess
incidence,
mortality,
disability-adjusted
life
years
(DALYs)
female-specific
cancers.
Age-standardized
rates
facilitated
cross-regional
comparisons,
accounting
differences
population
size
demographics.
The
socio-demographic
index
(SDI)
was
employed
categorize
regions
evaluate
correlations
between
cancer
burden
economic
level.
In
addition,
risk
factors
attributable
deaths
DALYs
assessed
based
on
comparative
assessment
model
GBD
project.
From
increased
at
varying
rates.
breast
accounted
2.08
million
incident
cases,
0.66
deaths,
20.25
globally.
comparison,
had
lower
burdens,
with
0.67
million,
0.30
0.47
respectively.
showed
positive
SDI,
while
cervical
exhibited
a
negative
correlation.
Attributable
cancer-associated
included
dietary
risks,
high
body-mass
(BMI),
fasting
plasma
glucose,
alcohol
use,
tobacco
low
physical
activity.
Additional
unsafe
sex
use
cancer,
BMI
occupational
risks
ovarian
cancer.
has
recent
decades,
significant
demographic
regional
discrepancies.
These
findings
highlight
urgent
need
targeted
public
interventions
mitigate
impact
Язык: Английский
IER5 Promotes Ovarian Cancer Cell Proliferation and Peritoneal Dissemination
Cancers,
Год журнала:
2025,
Номер
17(4), С. 610 - 610
Опубликована: Фев. 11, 2025
Background/Objective:
Ovarian
cancer
(OC)
is
one
of
the
most
lethal
gynecological
cancers,
having
a
worldwide
mortality
rate
66%
in
2020.
The
overall
5-year
relative
survival
only
21%
for
distant
stages,
due
to
lack
early
diagnosis.
Epithelial
OC,
common
high-grade
serous
carcinoma,
carries
p53
mutations
cases.
However,
we
found
that
immediate
response
5
gene
(IER5),
target
gene,
overexpressed
ovarian
cells.
molecular
mechanism
underlying
role
IER5
OC
has
not
been
well
studied.
We
previously
reported
promotes
dephosphorylation
and
activation
heat
shock
factor-1
(HSF1),
master
regulator
proteostasis,
which
induces
protein
(HSP)
expression.
Methods/Results:
Here
show
Ier5
mRNA
expression
higher
cells
(MOV,
ID8G,
HM-1)
compared
normal
also
floating
ascites
have
than
parental
strain.
Knockdown
suppressed
HSP
upregulation
proliferation
while
overexpression
promoted
upregulation.
Hsf1
showed
results
similar
knockdown.
Conclusions:
These
indicate
IER5-HSF1
pathway
contributes
peritoneal
dissemination
family
genes
related
poorer
prognosis
patients,
suggesting
potential
as
diagnostic
markers
therapeutic
targets.
Язык: Английский
Past and present: a bibliometric study on the treatment of recurrent ovarian cancer
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Июль 30, 2024
Ovarian
cancer
(OC)
is
a
gynecological
malignancy
with
high
mortality
rate
worldwide.
The
unfavorable
prognosis
of
OC
mainly
attributed
to
the
recurrent
propensity.
Recently,
from
has
exhibited
downward
trend.
These
favorable
patterns
are
likely
be
driven
by
advancements
in
novel
therapeutic
regimens.
However,
there
lack
visualize
analysis
application
these
new
drugs
on
women
(ROC).
Therefore,
we
aimed
provide
bibliometric
evolving
paradigms
ROC
treatment.
Язык: Английский
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer
Journal of Gynecologic Oncology,
Год журнала:
2024,
Номер
36
Опубликована: Окт. 23, 2024
To
investigate
an
association
between
the
gut
microbiome
and
efficacy
of
poly(ADP-ribose)
polymerase
inhibitors
(PARPi)
in
ovarian
cancer.
Язык: Английский
From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next Steps
Cancers,
Год журнала:
2024,
Номер
16(19), С. 3422 - 3422
Опубликована: Окт. 9, 2024
The
Korean
Gynecologic
Oncology
Group
(KGOG)
was
established
in
2002
and
is
the
only
organization
Korea
conducting
multi-center
clinical
trials
for
gynecologic
cancers.
Since
its
re-establishment
as
a
non-profit
2021,
KGOG
has
grown
significantly,
now
including
207
oncology
specialists
from
76
hospitals.
This
growth
testament
to
dedication
hard
work
of
all
those
involved
organization.
committed
maximizing
activation
research
through
policies
that
support
patients
with
rare
diseases
cancer
research,
focusing
on
strengthening
institutional
capacity,
equalizing
participation
opportunities,
enhancing
information
sharing.
A
significant
milestone
becoming
member
US
(GOG)
2005,
allowing
GOG
trials.
later
joined
Cancer
InterGroup
(GCIG)
strengthened
capabilities
by
hosting
first
Endometrial
Consensus
Conference—Clinical
Research
(ECCC-CR)
2023.
holds
biannual
meetings
symposia,
well
224
operating
committee
annually
review
discussions
Tumor
Site
Committee.
conducted
156
investigator-initiated
trial
(IIT)
or
sponsor-initiated
(SIT)
studies
KGOG-led
participated
research.
Currently,
18
are
registered,
10
preparation.
To
date,
68
papers
have
been
published.
conducts
six
national
projects
collaborates
external
organizations
such
NRG
Foundation,
Partners
(GOG-P),
GCIG,
East
Asian
Trial
group
(EAGOT),
Japanese
(JGOG).
Through
collaboration
renowned
international
institutions,
significantly
expanded
scope
achieving
noteworthy
outcomes.
report
not
introduces
history
recent
status
but
also
presents
exciting
future
direction
organization,
filled
potential
breakthroughs
advancements
Язык: Английский
Oncological safety of minimally invasive surgery in borderline ovarian tumor and ovarian cancer: a retrospective comparative study
Journal of Gynecologic Oncology,
Год журнала:
2024,
Номер
36
Опубликована: Ноя. 19, 2024
This
study
aimed
to
evaluate
the
oncological
safety
of
laparoscopic
surgery
for
patients
with
benign
tumors
who
underwent
at
our
facility
and
were
subsequently
diagnosed
borderline
ovarian
or
cancer.
We
conducted
a
retrospective
review
45
initially
institution
from
January
2009
April
2024.
Postoperative
pathological
examination
identified
32
cases
13
Laparoscopic
cystectomy
was
performed
in
14
(43.8%)
4
(30.8%)
cancer
cases.
Out
cystectomy,
8
staging
laparotomy,
whereas
6
only
tumor
cystectomy.
In
contrast,
none
completed
treatment
Recurrent
disease
observed
9.4%
cases,
all
which
successfully
managed
further
surgery.
group,
recurrence
occurred
31%
patients,
3
resulting
tumor-related
mortality.
is
suggested
be
oncologically
safe,
low
rate
no
adverse
impact
on
survival.
However,
cancer,
particularly
peritoneal
dissemination,
rapid
progression
remains
concern.
While
this
suggests
that
may
viable
option
tumors,
research
needed
validate
these
findings,
Язык: Английский